Compare Amylx Pharmaceuticals Inc (AMLX) vs Figs Inc (FIGS) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

FIGS trades at $10.04, down 2.81% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue grew to $631.10M in 2025 with a 66.61% gross margin, but net cash flow remains negative. Analyst consensus is Buy with a $18.00 price target, suggesting significant upside from current levels.

The stock offers growth potential through healthcare apparel demand and global expansion, but faces risks from valuation multiples (P/E 45.64), margin pressures, and persistent negative cash flow. Investor sentiment is mixed amid cost headwinds and competitive dynamics in the apparel sector.